BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. Registration information to attend the virtual sessions can be found here.

We will have a strong presence at the AACR annual meeting with 12 data presentations highlighting our leadership in antibody-drug conjugate innovation and the depth and potential of our growing oncology pipeline of targeted therapies, said Scott Peterson, Ph.D., Senior Vice President of Research at Seattle Genetics. Of key importance, a number of presentations will feature advances in our drug linker and payload components of ADCs. Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas.

Dr. Peterson added, In addition to our ADC technologies, we will also be presenting preclinical data highlighting the activity of our HER2 selective tyrosine kinase inhibitor tucatinib in preclinical models of HER2 mutant driven cancers and in the CNS setting. We look forward to sharing these presentations with the community at the second AACR virtual meeting.

Abstracts can be found at http://www.aacr.org and include the following poster presentations below.

New ADC Technology Advances

Abstract Title: Novel Framework for Quantifying Synergy in High-Throughput Drug Combination Cytotoxicity Experiments (Abstract #835)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics

Abstract Title: Discovery of a Tripeptide-Based Camptothecin Drug-Linker for Antibody-Drug Conjugates with Potent Antitumor Activity and a Broad Therapeutic Window (Abstract #2885)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: Characterization of Payload Release from a Novel Camptothecin Drug-Linker (Abstract #2895)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Pipeline Programs

Abstract Title: SGN-CD30C, a New CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti-Tumor Activity and Superior Tolerability in Preclinical Studies (Abstract #2889)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: Utilizing PDX Models to Better Understand Factors that Predict Response to SGN-CD228A, an Antibody-Drug Conjugate (ADC) for Solid Tumors (Abstract #2888)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: SGN-B6A: A New MMAE ADC Targeting Integrin Beta-6 in Multiple Carcinoma Indications (Abstract #2906)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: SEA-CD40 is a Non-Fucosylated Anti-CD40 Antibody with Potent Pharmacodynamic Activity in Preclinical Models and Patients with Advanced Solid Tumors (Abstract #5535)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Immune Response to Therapies 1

Commercial-Stage Programs

Abstract Title: Preclinical Characterization of Tucatinib in HER2-Amplified Xenograft and CNS Implanted Tumors (Abstract #1962)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Small Molecule Therapeutic Agents

Abstract Title: Tucatinib Inhibits Creatinine and Metformin Renal Tubule Secretion but has No Effect on Renal Function (GFR) (Abstract #3015)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib Inhibits CYP3A, CYP2C8 and P-gp-Mediated Elimination and is Impacted by CYP2C8 Inhibition in Healthy Volunteers (Abstract #3016)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib, a Selective Small Molecule HER2 Inhibitor, is Active in HER2 Mutant Driven Tumors (Abstract #4222)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Tyrosine Kinase and Phosphatase Inhibitors

Abstract Title: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urotherlial Cancers (Abstract #5581)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Immunotherapy

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the possible utility or application of the Companys technologies to develop therapeutic agents, the therapeutic potential of investigational agents and products, the Companys ADC leadership, future development activities and growing pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, including the risks that the Company may experience delays in its planned clinical trial initiations or otherwise experience failures or setbacks in its preclinical and clinical development programs due to the potential lack of efficacy or risk of adverse events or other factors. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Follow this link:
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24,...